Page last updated: 2024-11-12
rpl 554
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
ensifentrine: a phosphodiesterase 3/4 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9934746 |
| CHEMBL ID | 4594287 |
| SCHEMBL ID | 625876 |
| SCHEMBL ID | 20720900 |
| MeSH ID | M0501302 |
Synonyms (48)
| Synonym |
|---|
| LS-193855 , |
| rpl554 |
| 298680-25-8 |
| 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimidino(6,1-a)isoquinolin-4-one |
| rpl-554 |
| SCHEMBL625876 |
| 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one |
| 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one |
| CSOBIBXVIYAXFM-UHFFFAOYSA-N |
| 9,10-dimethoxy-2-(2.4.6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6.1-a]isoquinolin-4-one |
| ls-193,855 |
| ensifentrine [usan] |
| ensifentrine [who-dd] |
| n-(2-((2e)-9,10-dimetoxi-4-oxo-2-((2,4,6-trimetilfenil)imino)-6,7-dihidro-2h-pirimido(6,1-a)isoquinolein-3(4h)-il)etil)urea |
| urea, n-(2-(6,7-dihydro-9,10-dimethoxy-4-oxo-2-((2,4,6-trimethylphenyl)imino)-2h-pyrimido(6,1-a)isoquinolin-3(4h)-yl)ethyl)- |
| 3E3D8T1GIX , |
| ensifentrine |
| 1884461-72-6 |
| 2-(9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido(6,1-a)isoquinolin-3-yl)ethylurea |
| ensifentrine [inn] |
| DTXSID00183983 |
| unii-3e3d8t1gix |
| (2-{9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-2h,3h,4h,6h,7h-pyrimido[4,3-a]isoquinolin-3-yl}ethyl)urea |
| ensifentrine [usan:inn] |
| who 10726 |
| (e)-1-(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2h-pyrimido[6,1-a]isoquinolin-3(4h)-yl)ethyl)urea |
| SCHEMBL20720900 |
| vmx-554 |
| Q7277486 |
| SB19810 |
| 2-[9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-3-yl]ethylurea |
| BCP31840 |
| ensifentrina; ensifentrinum;rpl-554;rpl554;rpl 554 |
| ensifentrine (usan/inn) |
| D11743 |
| a]isoquinolin-3(4h)-yl}ethyl)urea |
| n-(2-{(2e)-9,10-dimethoxy-4-oxo-2-[(2,4,6- |
| trimethylphenyl)imino]-6,7-dihydro-2h-pyrimido[6,1- |
| MS-28860 |
| rpl-554;ensifentrinum |
| CHEMBL4594287 |
| A937318 |
| gtpl11865 |
| EX-A6633 |
| HY-111477 |
| (e/z)-ensifentrine |
| CS-0041580 |
| AKOS040746804 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Overall, RPL554 was well tolerated, and adverse events were generally mild and of equal frequency between placebo and active treatment groups." | ( Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Banner, KH; Burggraaf, J; Calzetta, L; Cazzola, M; Cohen, AF; de Kam, ML; Diamant, Z; Franciosi, LG; Kamerling, IM; Morelli, N; Page, CP; Singh, D; Spina, D; Walker, MJ; Zuiker, R, 2013) | 0.39 |
Dosage Studied
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1720050 | Induction of FEV1 in COPD patient at 18 ug/kg administered as single dose | 2020 | Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19 | Advances in the Development of Phosphodiesterase-4 Inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (23)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 10 (43.48) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 29.37
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.37) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (29.17%) | 5.53% |
| Reviews | 4 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (54.17%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||